LSX World Congress Concludes in Lisbon Focusing on Biotech Investment
LSX 世界大會在里斯本圓滿落幕，聚焦生物技術投資
The LSX World Congress Europe 2026 recently concluded in Lisbon, marking a pivotal moment for the life sciences sector.
2026年LSX歐洲世界大會近期於里斯本圓滿落幕，標誌著生命科學領域的關鍵時刻。
Held from March 25–26, the congress served as a central hub for investors and early-stage companies in biotech, medtech, and digital health.
該大會於3月25日至26日舉行，是生物技術、醫療技術和數位健康領域的投資者與早期企業的核心樞紐。
A major highlight was the 'Spring Innovation Week,' where the congress was held back-to-back with BIO-Europe Spring.
大會的一大亮點是「春季創新週」，當時大會與BIO-Europe Spring連續舉行。
Furthermore, regional delegations, such as those from Wallonia, leveraged the congress to showcase niche innovations to a global audience.
此外，如瓦隆地區等區域代表團也藉由此次大會向全球受眾展示其獨特的創新成果。
As the industry navigates a complex post-downturn funding environment, the Lisbon congress acted as a vital pulse-check, confirming that despite market challenges, the appetite for high-potential innovation remains strong.
在產業應對複雜的衰退後融資環境之際，里斯本大會發揮了至關重要的市場風向指標作用，證實儘管市場面臨挑戰，對於高潛力創新的需求依然強勁。
This convergence of expertise reinforces Lisbon's position as a key destination for European life science capital.
此次專業領域的匯聚，進一步鞏固了里斯本作為歐洲生命科學資本關鍵目的地的地位。
